Parkinson's Disease is a new study from Decision Resources, Inc. that identifies areas of opportunity for companies competing in the Parkinson's disease (PD) drug development marketplace. Our research indicates that sales for most drug classes used to treat PD will grow throughout the 2000-2010 forecast period of this study because of the growing number of PD patients, long disease duration, and the increased use of polytherapy with some of the newer, more-expensive agents.
(Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION)
Emerging Therapies for Parkinson's Will Be Used to Delay the Need for Levodopa
The recent trend toward levodopa-sparing strategies will result in the increased use of dopamine agonists. We expect the two newer, non-ergot-derived dopamine agonists-ropinirole (GlaxoSmithKline's Requip) and pramipexole (Pharmacia's Mirapex)-to remain the top-sellers in the United States during our forecast period, with ropinirole seeing a boost in sales upon the introduction of a once-daily, controlled-release formulation by 2005. This increase will come at the expense of the older dopamine agonists. Two novel dopamine agonists-Schwarz Pharma's transdermal rotigotine and Pharmacia's PNU- 95666-are expected to enter the market by 2005. Schwarz Pharma's rotigotine CDS Parkinson Patch will offer more continuous dopaminergic treatment than other available oral therapies, and is therefore likely to be perceived as novel and unique. There is some evidence to suggest that non-pulsatile dopaminergic stimulation might not only delay motor-complications in early Parkinson patients, but also reverse dyskinesias in advanced patients. If this is true--and if rotigotine does, in fact, provide more steady dopaminergic stimulation than orally administered PD therapies--the transdermally delivered drug may carve out a niche for itself in the segment of the PD population who prefer a transdermal medication.
Increased Use of Combination Therapies Will Be a Major Contributor to Market Growth
As new drugs are marketed for use as adjuncts to levodopa, more PD patients will end up taking two or more medications to control both their parkinsonian symptoms and the motor complications caused by chronic levodopa use. The biggest contributors to growth in this sector through 2010 will be the novel glutamate antagonists, the monoamine oxidase-B (MAO-B) inhibitors, and other novel therapies expected to enter the market closer to the end of our forecast period. Additionally, if any of these agents were found to elicit neuroprotective effects, their potential market would be vastly increased because they would be administered to nearly all early-stage PD patients.
Parkinson's Disease offers invaluable market intelligence for pharmaceutical companies competing in this market, and is a part of Cognos, one of six Pharmacor services available from Decision Resources that evaluate the commercial potential of drugs in research and development.
Decision Resources, Inc., is a world leader in research publications and advisory services designed to help clients shape strategy, allocate resources, and master their chosen markets. Founded as a subsidiary of Arthur D. Little, Inc., the company has provided strategic information services for 30 years, assessing international pharmaceutical and health care industry trends. Visit Decision Resources at http://www.dresources.com/.
Contact Frank Sama, 781.296.2553 (tel), 781.296.2550 (fax), or firstname.lastname@example.org. In Europe, contact Francoise Bidart, +32.2.351.4082 (tel), +32.2.351.2347 (fax), or email@example.com. In Japan, contact Makiko Yoshimoto, +81.3.5401.2615 (tel), +81.3.5401.2617 (fax), or firstname.lastname@example.org.
AP Archive: http://photoarchive.ap.org/
PRN Photo Desk, 888-776-6555 or 212-782-2840
SOURCE: Decision Resources, Inc.
Contact: Frank Sama of Decision Resources, Inc., +1-781-296-2553,